AM-Pharma

AM-Pharma is a biopharmaceutical company based in Utrecht, Netherlands, focusing on the preclinical and clinical development of new therapies for inflammatory and infectious diseases. The company’s lead product under development is based on endogenous proteins, protein-derived peptides, and molecules naturally present in the human body. Its innovative recombinant human alkaline phosphatase therapeutic (recAP) is at the forefront of treating acute kidney injury (AKI).AKI, primarily caused by sepsis, remains a challenging clinical issue. Currently, there are millions of AKI patients worldwide, but due to the failure of most drug clinical trials, the mortality rate of AKI patients remains high.Additionally, AM-Pharma is exploring other indications for recAP, such as ulcerative colitis (UC), necrotizing enterocolitis (NEC), and hypophosphatasia (HPP).